TherapeuticsMD Inc. (TXMD) had a rough trading day for Wednesday October 16 as shares tumbled 5.75%, or a loss of $-0.225 per share, to close at $3.69. After opening the day at $3.93, shares of TherapeuticsMD Inc. traded as high as $3.97 and as low as $3.60. Volume was 3.3 million shares over 11,242 trades, against an average daily volume of n/a shares and a total float of 241.22 million.
As a result of the decline, TherapeuticsMD Inc. now has a market cap of $890.11 million. In the last year, shares of TherapeuticsMD Inc. have traded between a range of $6.09 and $1.82, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.
TherapeuticsMD Inc is a major drug manufacturing with a focus on creating and commercializing products targeted exclusively for women. The company intends to commercialize advanced hormone therapy pharmaceutical products. TherapeuticsMD’s drug candidates that have completed clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and discomfort. The company relies on third parties for the production of clinical and commercial quantities of its drug candidates.
TherapeuticsMD Inc. is based out of Boca Raton, FL and has some 241 employees. Its CEO is Robert G. Finizio.
TherapeuticsMD Inc. is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
